Defense · Report Line
The chief executive of the UK’s biggest tech company has said that advances in artificial intelligence will deliver a cure for cancer within the next few decades. Rene Haas, CEO of Arm Holdings, claimed that AI would be able to solve the problem of modelling DNA markers impacted by cancer, which is currently ‘too complex’ for humans or current AI systems. Headquartered in Cambridge, Arm designs the semiconductor architecture used in billions of smartphones, smartwatches, and other devices globally, as well as an increasing share of AI chips in data centres.
The company has become one of the biggest beneficiaries of the global AI boom, becoming the most valuable UK firm in history earlier this year with a market cap above $400 billion. Haas stated, ‘AI is going to find a cure for cancer that today you and I, other humans, could not in our lifetimes. I believe in our lifetime, AI will help cure cancer.’ He explained that modelling a cell, a human, or how a DNA marker is impacted by cancer is too complex for humans and current AI systems.
However, as AI models are fed more data and computers become more sophisticated, they will eventually solve this problem. Recent AI breakthroughs in healthcare have fueled optimism about AI’s potential to accelerate medical research. In 2024, Google DeepMind unveiled AlphaFold 3, an AI model capable of predicting protein, DNA, RNA, and drug molecule interactions—a key milestone in discovering new cancer treatments.
Isomorphic Labs, a DeepMind spin-off, began preparing the first human clinical trials of drugs designed using AI systems. Pharmaceutical companies like AstraZeneca, Eli Lilly, and Sanofi have also formed multi-billion-dollar partnerships with AI to identify new cancer treatments. Haas noted that one of the key challenges to achieving this potential is the availability of AI chips, which are currently facing supply chain issues.
Source: The Independent
